Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Deals
|
M&A
|
Financials
|
Strategy
|
Lifecycle Management
|
Legal
|
Scrip   
Vernalis pays $33 million to regain frovatriptan royalty rights
09 March 2010
Eleanor Malone

eleanor.malone@informa.com

The UK firm Vernalis has regained full rights to the royalties on its only marketed product, the migraine treatment frovatriptan. It made a one-off net cash payment of $32.57 million to Paul Capital Healthcare (PCH), which acquired 2.1 million warrants over Vernalis shares.

The deal means...



Please Login to read the full article.
 
Not a subscriber? Request a FREE Trial Subscribe to Scrip
RELATED CONTENT
NEWS Scrip News Other Informa News
ANALYSIS Scrip Analysis Other Informa Analysis
COMMENT Scrip Comment Other Informa Comment
FEATURES Scrip Features Other Informa Features
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm